Amgen AI Stock Analysis
Want to see AMGN full AI Analyst Report?
Amgen (AMGN) AI Stock Analysis
Amgen
(NASDAQ:AMGN)
AMGN’s score is driven primarily by strong technical momentum and a very constructive earnings update (raised 2026 guidance, broad product growth, and positive late-stage pipeline progress). These positives are tempered by meaningful balance-sheet leverage risk and a valuation that is not cheap, though supported by a moderate dividend.
Amgen Key Performance Indicators (KPIs)
Revenue by TypeDistinguishes between different revenue streams, such as product sales and royalties, providing insights into Amgen's business model and diversification.
Product sales are the company’s growth engine—broad-based, accelerating and the main reason Amgen raised 2026 guidance—driven by multiple high-growth brands that more than offset the Prolia/XGEVA decline. “Other” revenue is much smaller and lumpy but has lifted recently, aligning with BD receipts and the $100M upfront that will bump Q3; don’t treat it as recurring. Key risks: higher cost-of-sales/profit-sharing and planned R&D/capex step-ups could pressure margins even as product-led top-line momentum continues.
Amgen (AMGN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $240.11B
- Dividend Yield
- 2.24%
- Average Volume (3M)
- 2.76M
- Price to Earnings (P/E)
- 25.5
- Beta (1Y)
- 0.26
- Revenue Growth
- 8.60%
- EPS Growth
- 33.48%
- Country
- US
- Employees
- 31,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Amgen Business Overview & Revenue Model
Company Description
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span...
How the Company Makes Money
Amgen makes money primarily by selling prescription medicines, with revenue largely driven by net product sales (gross sales minus rebates, chargebacks, returns, and other allowances common in pharmaceuticals). Its key revenue streams include: (1) Sa...
Amgen Earnings Call Summary
The call was strongly optimistic, supported by 8% revenue growth, 27% growth from the six key growth drivers, broad product momentum, positive late-stage clinical results, strong free cash flow and raised 2026 revenue and EPS guidance. The principal negatives were a 6% TEPEZZA sales decline, expected fourth-quarter expense increases, higher full-year other expense guidance and some uncertainty around upcoming symptomatic Sjogren's data and international MariTide reimbursement. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Amgen now expects total revenues in the range of $38.9 billion to $39.7 billion and non-GAAP earnings per share between $22.90 and $23.70; non-GAAP other income and expense is expected to be in the range of $2 billion to $2.1 billion of expense, full-year non-GAAP operating margin as a percentage of product sales is expected to be roughly 45% to 46%, other revenue is expected to be approximately $1.9 billion, the non-GAAP tax rate is expected to be in the range of 15% to 16.5%, share repurchases are expected not to exceed $3 billion, and capital expenditures are expected to be approximately $2.6 billion. For the fourth quarter, Amgen expects a meaningful sequential increase in operating expenses, including a sequentially higher cost of sales margin and higher SG&A expense. Looking ahead to 2027, Amgen does not anticipate a step-down in operating margin compared with its 2026 guidance.
Amgen Financial Statement Overview
Summary
Strong profitability and cash generation support the score (TTM gross margin ~74%, net margin ~24%, operating cash flow ~$12B and free cash flow ~$9.6B). The main offset is balance-sheet risk: leverage is high (TTM debt-to-equity ~3.8x; total debt ~$54B) and profitability/free cash flow have shown some volatility.
Income Statement
84Very PositiveBalance Sheet
43NeutralCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.90B | 36.74B | 33.42B | 28.19B | 26.32B | 25.98B |
| Gross Profit | 27.88B | 26.01B | 20.57B | 19.77B | 19.92B | 19.52B |
| EBITDA | 18.17B | 16.90B | 13.36B | 14.80B | 12.17B | 11.30B |
| Net Income | 9.39B | 7.71B | 4.09B | 6.72B | 6.55B | 5.89B |
Balance Sheet | ||||||
| Total Assets | 96.05B | 90.59B | 91.84B | 97.15B | 65.12B | 61.16B |
| Cash, Cash Equivalents and Short-Term Investments | 13.19B | 9.13B | 11.97B | 10.94B | 9.30B | 8.04B |
| Total Debt | 54.01B | 54.60B | 60.10B | 64.61B | 38.95B | 33.31B |
| Total Liabilities | 81.70B | 81.93B | 85.96B | 90.92B | 61.46B | 54.47B |
| Stockholders Equity | 14.35B | 8.66B | 5.88B | 6.23B | 3.66B | 6.70B |
Cash Flow | ||||||
| Free Cash Flow | 9.58B | 8.10B | 10.39B | 7.36B | 8.79B | 8.38B |
| Operating Cash Flow | 12.04B | 9.96B | 11.49B | 8.47B | 9.72B | 9.26B |
| Investing Cash Flow | -2.63B | -1.94B | -1.05B | -26.20B | -6.04B | 733.00M |
| Financing Cash Flow | -5.66B | -10.86B | -9.41B | 21.05B | -4.04B | -8.27B |
Amgen Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMGN, the sentiment is Neutral. The current price of 443.89 is below the 20-day moving average (MA) of 458.95, above the 50-day MA of 428.15, and above the 200-day MA of 380.25, indicating a neutral trend. The MACD of 7.68 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 25.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMGN.
Amgen Risk Analysis
Amgen disclosed 32 risk factors in its most recent earnings report. Amgen reported the most risks in the "Ability to Sell" category.
Latest Risks Added
3 New RisksAmgen Peers Comparison
Overall Rating
AMGN75Outperform
NVS72Outperform
ABBV71Outperform
JNJ70Outperform
BMY66Neutral
MRK64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $240.11B | 25.54 | 85.59% | 2.24% | 8.60% | 33.48% | |
| 72Outperform | $289.35B | 30.00 | 24.24% | 3.05% | 1.64% | -28.72% | |
| 71Outperform | $505.56B | 49.05 | -202.35% | 2.42% | 10.68% | 338.08% | |
| 70Outperform | $670.92B | 41.34 | 19.55% | 1.94% | 7.81% | -35.95% | |
| 66Neutral | $125.40B | 13.18 | 43.88% | 4.23% | 4.19% | 52.55% | |
| 64Neutral | $339.66B | 139.17 | 5.29% | 2.47% | 5.21% | -86.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AMGN | Amgen Inc | 443.89 | 113.12 | 34.20% | |
| BMY | Bristol-Myers Squibb Company | 59.56 | 15.28 | 34.51% | |
| JNJ | Johnson & Johnson | 272.70 | 73.29 | 36.76% | |
| MRK | Merck & Company | 137.78 | 42.81 | 45.08% | |
| NVS | Novartis AG | 155.21 | 30.35 | 24.30% | |
| ABBV | Abbvie | 286.01 | 56.60 | 24.67% |
Amgen Corporate Events
Amgen Adds David Gibbs to Board of Directors
PositiveOn Oct. 26, 2026, Amgen appointed David W. Gibbs, the recently retired president and chief executive officer of Yum! Brands, to its Board of Directors, effective immediately. Gibbs joins the Audit Committee and the Compensation and Management Develop...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
